Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Hematology

Treatment Options for Acute and Cutaneous Porphyria

At a Glance

Porphyria treatment depends on the specific type. Acute hepatic porphyria (AHP) attacks are treated with IV hemin, while Givosiran can prevent them. Skin porphyrias like PCT are managed with phlebotomy, and EPP is treated with Afamelanotide implants.

Treatment for porphyria has moved beyond just managing pain. Today, modern therapies target the biological “bottleneck” in your heme assembly line to either stop an active crisis or prevent one from ever starting [1][2]. Because every case is unique, your specialist will customize your treatment plan based on your specific type and the frequency of your symptoms.

Treatments for Acute Hepatic Porphyria (AHP)

When an acute attack occurs, it is considered a medical emergency. The goal of treatment is to “turn off” the overactive production of neurotoxic chemicals [1].

Emergency Care: IV Hemin

Intravenous hemin (sold as Panhematin or Normosang) is the standard of care for stopping an active attack [1][3].

  • How it works: By providing your body with “finished” heme, it signals your liver to stop the “assembly line” from overproducing toxic precursors like ALA and PBG [1][4].
  • Administration Safety: Hemin is highly irritating to veins and frequently causes severe phlebitis or vein sclerosis if given through a small peripheral IV. You should advocate for administration via a large vein or a central line (like a PICC or port), especially if multiple doses are required [3].
  • The Result: It is highly effective at reducing pain and the need for opioids, helping attacks resolve much faster than they would with supportive care alone [5].

Long-Term Prevention: Givosiran

For adults who suffer from frequent, recurrent attacks, a newer therapy called Givosiran (Givlaari) has been a breakthrough [6][7].

  • The Mechanism: This is an “RNA interference” (RNAi) therapy. It works like a “silencer” for the ALAS1 enzyme, preventing the toxic “pile-up” from happening in the first place [8][9].
  • Impact on Life: Most patients on Givosiran see a massive reduction in the number of attacks and hospital visits, leading to a significantly improved quality of life [10][11].
  • Monitoring and Safety: While generally safe, your doctor must monitor your liver enzymes (ALT/AST) regularly due to the risk of severe liver toxicity. They will also monitor your kidney function and homocysteine levels, as Givosiran can sometimes cause shifts that require Vitamin B6 supplementation [6][12].

Treatments for Cutaneous (Skin) Porphyrias

For types that affect the skin, the goal is to reduce the concentration of porphyrins in the body or increase the skin’s natural defenses.

Porphyria Cutanea Tarda (PCT)

PCT is highly treatable and can often be put into complete remission [13].

  • Phlebotomy: This involves removing small amounts of blood (similar to a blood donation) to lower the iron levels in your liver, which helps the heme assembly line function normally again [14][15].
  • Low-Dose Hydroxychloroquine: This medication helps your liver flush out excess porphyrins through your urine [16].
  • Treating the Root Cause: Because PCT is often triggered by Hepatitis C, modern antiviral treatments can often cure the infection and resolve the porphyria simultaneously [13][17].

Erythropoietic Protoporphyria (EPP)

For EPP, where the primary issue is excruciating pain from sun exposure, a specialized treatment called Afamelanotide (Scenesse) is available [18].

  • How it works: This is a small implant placed under the skin. It stimulates the production of melanin (your skin’s natural pigment), providing a “physical shield” against the light that triggers reactions [18][19].
  • The Result: Patients often report a significant increase in their “pain-free” time in the sun, allowing them to participate in outdoor activities that were previously impossible [20][21].

A Note on Supportive Care

Regardless of the type, management always includes supportive care, such as specialized pain management, anti-nausea medications, and sometimes intravenous glucose [22][23]. Always work with a specialist who can ensure your treatments are safe for your specific enzyme deficiency. You should carry an emergency letter and a medical alert bracelet, as ER doctors may not know which common pain or anti-nausea medications are unsafe [24].

Return to Home

Common questions in this guide

How is an acute hepatic porphyria (AHP) attack treated?
An active acute hepatic porphyria (AHP) attack is considered a medical emergency. It is primarily treated with intravenous hemin, which signals your liver to stop overproducing toxic chemicals, significantly reducing pain and speeding up recovery.
What is Givosiran used for in porphyria?
Givosiran is a preventative medication for adults who suffer from frequent, recurrent acute porphyria attacks. It works by silencing a specific liver enzyme to prevent the buildup of toxic chemicals, which massively reduces the number of attacks and hospital visits.
Why do I need to monitor my liver and kidney function while on Givosiran?
Because Givosiran can sometimes cause shifts in your liver enzymes, kidney function, and homocysteine levels, regular blood tests are required. This monitoring helps your doctor ensure the treatment remains safe and helps determine if you need supplements like Vitamin B6.
How is Porphyria Cutanea Tarda (PCT) treated?
PCT is highly treatable and often managed through therapeutic phlebotomy, which removes small amounts of blood to lower iron levels in your liver. Doctors may also prescribe low-dose hydroxychloroquine to help your body flush out excess porphyrins through your urine.
Is there a treatment to help with the extreme sun sensitivity caused by EPP?
Yes, patients with EPP can receive a specialized implant called Afamelanotide placed under the skin. This implant stimulates your skin's natural melanin production, creating a physical shield against light and allowing for much more pain-free time in the sun.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.If I experience an acute attack, how quickly can I access IV hemin at my local hospital?
  2. 2.Am I a candidate for Givosiran to prevent my frequent attacks, and what monitoring (like homocysteine or liver enzymes) will I need?
  3. 3.For my PCT, is therapeutic phlebotomy or low-dose hydroxychloroquine more appropriate for my specific iron levels?
  4. 4.Since I have PCT, have we screened for Hepatitis C or iron overload (hemochromatosis)?
  5. 5.Can we discuss the Afamelanotide implant to help increase my pain-free sun exposure for my EPP?
  6. 6.Are there specific vitamin supplements, like B6 or D, that I should be taking alongside my treatment?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (24)
  1. 1

    A novel HMBS gene mutation in acute intermittent porphyria: a case report of abdominal pain, seizures, and reversible neuroimaging findings.

    Dong W, Zeng B, Wang X, et al.

    Frontiers in genetics 2025; (16()):1551832 doi:10.3389/fgene.2025.1551832.

    PMID: 40110035
  2. 2

    Efficacy and safety of givosiran for acute hepatic porphyria: Final results of the randomized phase III ENVISION trial.

    Kuter DJ, Bonkovsky HL, Monroy S, et al.

    Journal of hepatology 2023; (79(5)):1150-1158 doi:10.1016/j.jhep.2023.06.013.

    PMID: 37479139
  3. 3

    A Delayed Progression of Porphyria-Associated Kidney Disease After Hemin Therapy in a Patient with Acute Intermittent Porphyria: A Case Report.

    Ishimura T, Wells KJ, Shimada A, et al.

    Internal medicine (Tokyo, Japan) 2026; doi:10.2169/internalmedicine.7131-26.

    PMID: 42144323
  4. 4

    Effects of hemin and hemodialysis in a patient with acute intermittent porphyria and renal failure.

    Attarian S, Yu C, Anderson KE, Friedman EW

    Blood advances 2017; (1(14)):915-917 doi:10.1182/bloodadvances.2017005660.

    PMID: 29296735
  5. 5

    Comparative effectiveness of human hematin and heme arginate in the management of porphyria attacks: an observational study across three hospitals in Colombia.

    Rave-B EE, Rojas-Henao NA, Valencia-Quintero AF, Nieto-López ES

    Hospital practice (1995) 2025; (53(1)):2520743 doi:10.1080/21548331.2025.2520743.

    PMID: 40545748
  6. 6

    Long-term follow-up of givosiran treatment in patients with acute intermittent porphyria from a phase 1/2, 48-month open-label extension study.

    Sardh E, Balwani M, Rees DC, et al.

    Orphanet journal of rare diseases 2024; (19(1)):365 doi:10.1186/s13023-024-03284-w.

    PMID: 39363243
  7. 7

    Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria.

    Sardh E, Harper P, Balwani M, et al.

    The New England journal of medicine 2019; (380(6)):549-558 doi:10.1056/NEJMoa1807838.

    PMID: 30726693
  8. 8

    Pharmacokinetics and Pharmacodynamics of the Small Interfering Ribonucleic Acid, Givosiran, in Patients With Acute Hepatic Porphyria.

    Agarwal S, Simon AR, Goel V, et al.

    Clinical pharmacology and therapeutics 2020; (108(1)):63-72 doi:10.1002/cpt.1802.

    PMID: 31994716
  9. 9

    Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study.

    Wang B, Ventura P, Takase KI, et al.

    Orphanet journal of rare diseases 2022; (17(1)):327 doi:10.1186/s13023-022-02463-x.

    PMID: 36028858
  10. 10

    Patient experience with acute hepatic porphyria before and after long-term givosiran treatment in a qualitative interview study.

    Naik H, Brown M, Meninger S, Lombardelli S

    Molecular genetics and metabolism reports 2025; (42()):101174 doi:10.1016/j.ymgmr.2024.101174.

    PMID: 39811158
  11. 11

    Givosiran for the treatment of acute hepatic porphyria.

    Ricci A, Ventura P

    Expert review of clinical pharmacology 2022; (15(4)):383-393 doi:10.1080/17512433.2022.2075848.

    PMID: 35531651
  12. 12

    Dysregulation of homocysteine homeostasis in acute intermittent porphyria patients receiving heme arginate or givosiran.

    To-Figueras J, Wijngaard R, García-Villoria J, et al.

    Journal of inherited metabolic disease 2021; (44(4)):961-971 doi:10.1002/jimd.12391.

    PMID: 33861472
  13. 13

    Ledipasvir/Sofosbuvir Is Effective as Sole Treatment of Porphyria Cutanea Tarda with Chronic Hepatitis C.

    Bonkovsky HL, Rudnick SP, Ma CD, et al.

    Digestive diseases and sciences 2023; (68(6)):2738-2746 doi:10.1007/s10620-023-07859-8.

    PMID: 36811718
  14. 14

    A Rare Case of Hereditary Hemochromatosis Presenting With Porphyria Cutanea Tarda.

    Varada N, Tun KM, Chang MJ, et al.

    Cureus 2023; (15(7)):e41299 doi:10.7759/cureus.41299.

    PMID: 37539416
  15. 15

    Clinical applications of therapeutic phlebotomy.

    Kim KH, Oh KY

    Journal of blood medicine 2016; (7()):139-44 doi:10.2147/JBM.S108479.

    PMID: 27486346
  16. 16

    Porphyria cutanea tarda: Recent update.

    Singal AK

    Molecular genetics and metabolism 2019; (128(3)):271-281 doi:10.1016/j.ymgme.2019.01.004.

    PMID: 30683557
  17. 17

    Can curative antivirals benefit porphyria cutanea tarda in hepatitis C patients?

    Hatch MM, Nawas Z, Kollipara R, Tyring SK

    Journal of the European Academy of Dermatology and Venereology : JEADV 2017; (31(4)):e194 doi:10.1111/jdv.13936.

    PMID: 27550066
  18. 18

    Advances in the management of erythropoietic protoporphyria - role of afamelanotide.

    Lane AM, McKay JT, Bonkovsky HL

    The application of clinical genetics 2016; (9()):179-189 doi:10.2147/TACG.S122030.

    PMID: 28003770
  19. 19

    Incidence and Prevalence of Erythropoietic Protoporphyria in Colombia Between 2014 and 2018.

    Jaramillo-Calle DA

    Actas dermo-sifiliograficas 2021; (112(2)):186-188 doi:10.1016/j.ad.2019.04.019.

    PMID: 32991848
  20. 20

    Erythropoietic Protoporphyria and X-Linked Protoporphyria: pathophysiology, genetics, clinical manifestations, and management.

    Balwani M

    Molecular genetics and metabolism 2019; (128(3)):298-303 doi:10.1016/j.ymgme.2019.01.020.

    PMID: 30704898
  21. 21

    Afamelanotide for Erythropoietic Protoporphyria.

    Langendonk JG, Balwani M, Anderson KE, et al.

    The New England journal of medicine 2015; (373(1)):48-59 doi:10.1056/NEJMoa1411481.

    PMID: 26132941
  22. 22

    Protocol For Patients With Suspected Acute Porphyria.

    Castelbón Fernández FJ, Solares Fernandez I, Arranz Canales E, et al.

    Revista clinica espanola 2020; (220(9)):592-596 doi:10.1016/j.rce.2019.10.012.

    PMID: 32143835
  23. 23

    Acute hepatic porphyrias for the neurologist: current concepts and perspectives.

    Souza PVS, Badia BML, Farias IB, et al.

    Arquivos de neuro-psiquiatria 2021; (79(1)):68-80 doi:10.1590/0004-282X20200096.

    PMID: 33656101
  24. 24

    Guide for the classification of porphyrias using state-of-the-art reverse-phase high-performance liquid chromatography.

    Laguna J, Wijngaard R, Marés L, et al.

    Scandinavian journal of clinical and laboratory investigation 2025; (85(5)):327-339 doi:10.1080/00365513.2025.2524714.

    PMID: 40600928

This page provides educational information about porphyria treatments. Always consult your hematologist or specialist before starting or changing any medication or treatment plan.

Get notified when new evidence is published on Porphyria.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.